The FDA on March 10 approved Pfizer Inc.’s Zavzpret for the treatment of acute migraine with or without aura in adult patients. While the drug is not the first migraine nasal spray on the market, it is the first calcitonin gene-related peptide (CGRP) receptor antagonist in that format, boasting a mechanism of action that can provide pain relief in as little as 15 minutes, according to phase 3 study data. Zavzpret enters a competitive market basket, which includes Impel Pharmaceuticals’ nasal spray Trudhesa. Impel in November said the drug has generated about 50,000 prescriptions since its commercial launch in October 2021. For the treatment of acute migraine, Trudhesa currently holds covered or better status for 59% of all insured lives under the pharmacy benefit. Coverage typically requires prior authorization and/or step therapy.
SOURCE: MMIT Analytics, as of 3/15/23